Jefferies London Healthcare Conference 2025 November 20, 2025 9:30 AM ESTCompany ParticipantsPeter Dannenbaum - Vice ...

As Merck looks for growth opportunities ahead of Keytruda’s tumble over the patent cliff, the company’s future now looks a bit brighter in the glow of two late-stage trial wins for cancer drug Welireg ...

RAHWAY, N.J.,, October 28, 2025--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3 LITESPARK-022 trial ...

Merck (NYSE:MRK) announced on Thursday that the FDA has granted priority review for two of its marketing applications aimed at expanding the U.S. indications of injectable and intravenous versions of ...

KEYTRUDA monotherapy now approved as neoadjuvant treatment, continued as adjuvant treatment combined with radiotherapy with or without concomitant cisplatin then as monotherapy Based on results of ...

Merck & Co. and Eisai previously had high hopes for their Keytruda-Lenvima combination in a liver cancer subtype based on positive progression-free survival data, but now the combo’s promise has once ...

President Donald Trump put pharmaceutical CEOs on notice, demanding they lower drug prices or he promised to get involved. He penned a letter to 17 CEOs in July, outlining what he wants from the ...

(Reuters) -Merck & Co posted higher third-quarter revenue on Thursday, as growth from its blockbuster cancer drug Keytruda offset falling sales from human papillomavirus vaccine Gardasil in China.

Merck reported third-quarter earnings and revenue that topped estimates in part due to strong demand for its cancer immunotherapy Keytruda, and narrowed its full-year profit outlook to reflect lower ...

Merck shares have floundered this year, as the company speeds like a whistling locomotive toward the expiration of the patents protecting its megablockbuster cancer immunotherapy Keytruda.